Unfortunately, there is currently no certain effective treatment, and according to the recent solidarity study conducted by the WHO [194,197], compared with placebo, none of the retasked drugs, including remdesivir, HCQ and IFN-β as a single, as well as IFN-β plus lopinavir and lopinavir coadministered with ritonavir as a combinatorial therapy, were effective in survival, initiation of ventilation and hospitalization length in COVID-19 patients. Here, IFNB1 is linked to COVID-19.